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REPORT
Leigh Syndrome with Nephropathy and CoQ10 Deﬁciency Due
to decaprenyl diphosphate synthase subunit 2 (PDSS2) Mutations
Luis Carlos Lo´pez, Markus Schuelke, Catarina M. Quinzii, Tomotake Kanki,
Richard J. T. Rodenburg, Ali Naini, Salvatore DiMauro, and Michio Hirano
Coenzyme Q10 (CoQ10) is a vital lipophilic molecule that transfers electrons from mitochondrial respiratory chain com-
plexes I and II to complex III. Deﬁciency of CoQ10 has been associated with diverse clinical phenotypes, but, in most
patients, the molecular cause is unknown. The ﬁrst defect in a CoQ10 biosynthetic gene, COQ2, was identiﬁed in a child
with encephalomyopathy and nephrotic syndrome and in a younger sibling with only nephropathy. Here, we describe
an infant with severe Leigh syndrome, nephrotic syndrome, andCoQ10 deﬁciency inmuscle andﬁbroblasts andcompound
heterozygous mutations in the PDSS2 gene, which encodes a subunit of decaprenyl diphosphate synthase, the ﬁrst enzyme
of the CoQ10 biosynthetic pathway. Biochemical assays with radiolabeled substrates indicated a severe defect in decaprenyl
diphosphate synthase in the patient’s ﬁbroblasts. This is the ﬁrst description of pathogenic mutations in PDSS2 and
conﬁrms the molecular and clinical heterogeneity of primary CoQ10 deﬁciency.
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Coenzyme Q10 (CoQ10), a lipophilic molecule present in
all cell membranes, functions as an electron carrier in the
mitochondrial respiratory chain, where it transports elec-
trons from complexes I and II to complex III. In addition,
CoQ10 is an antioxidant, a membrane stabilizer, and a reg-
ulator of mitochondrial permeability transition pores, and
its oxidized form serves as a cofactor for uncoupling pro-
teins in brown adipose tissue.1,2
CoQ10 is composed of a benzoquinone and a deca-
prenyl side chain (ﬁg. 1). Whereas the quinone ring is
derived from the amino acids tyrosine or phenylalanine,
the isoprenoid side chain is produced by addition of is-
opentenyl diphosphate molecules to farnesyl diphos-
phate or geranylgeranyl diphosphate (derived from mev-
alonate pathway) in multiple steps catalyzed by deca-
prenyl diphosphate synthase (ﬁg. 1). After para-hydrox-
ybenzoate (PHB) and decaprenyl diphosphate are pro-
duced, at least seven enzymes catalyze condensation,
methylation, decarboxylation, and hydroxylation reac-
tions to synthesize CoQ10.
1,2
CoQ10 deﬁciency (MIM #607426) has been associated
with autosomal recessive neurological disorders that are
responsive to CoQ10 supplementation. Clinical phenotypes
include: (1) a predominantly myopathic form character-
ized by recurrent myoglobinuria and CNS involvement
with seizures, ataxia, or mental retardation3–5; (2) child-
hood-onset cerebellar ataxia, which is often associated
with seizures, muscle weakness, mental retardation, pyra-
midal tract signs, and peripheral neuropathy6–8; (3) a mul-
tisystem infantile variant with encephalopathy, cardio-
myopathy, ataxia, optic-nerve atrophy, deafness, and ne-
phropathy9–12; (4) Leigh syndrome with growth retarda-
tion, ataxia, and deafness13; and (5) isolated childhood- or
adult-onset myopathy.14–15 Recently, in two siblings with
the multisystem infantile form of CoQ10 deﬁciency, we
identiﬁed the ﬁrst mutation in a CoQ10 biosynthetic gene,
COQ2 (MIM #609825), which encodes PHB-polyprenyl
transferase, the enzyme that catalyzes the second dedi-
cated step in CoQ10 biosynthesis.
12 The absence of muta-
tions in COQ2 in other patients with CoQ10 deﬁciency
suggests that mutations in other CoQ10 biosynthetic genes
may exist. Identiﬁcation of the molecular causes of the
CoQ10 deﬁciency will allow early and accurate diagnosis,
which is particularly critical because patients can respond
to replacement therapy.
Here, we describe a male infant who presented with neo-
natal pneumonia and hypotonia. He was the second child
of healthy, nonconsanguineous white parents, and his el-
der sister was healthy. At age 3mo, he developed refractory
left-sided seizures with secondary generalization, despite
various combinations of antiepileptic drugs. He became
progressively ﬂoppy (ﬁg. 2A) and had difﬁculties feeding
because of exhaustion. At age 7 mo, severe episodic vom-
iting prompted duodenal tube feeding, and he rapidly de-
veloped widespread edema. His low serum albumin of 4.3
g/liter (normal range 35–52) and massive proteinuria led
to the diagnosis of nephrotic syndrome. His serum lactate
was markedly elevated (7.5 mmol/liter; normal !2.0), and
his lactate:pyruvate ratio was at the upper limit of normal
(21; normal !20). Electroencephalogram (EEG) studies re-
vealed focal spikes over the right hemisphere (ﬁg. 2C),
with occasional secondary generalization. The absence of
purposeful gaze and visual evoked-potential responses, to-
gether with normal funduscopic ﬁndings, suggested cor-
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Figure 1. CoQ10 biosynthetic pathway. Isopentenyl diphosphates
derived from the mevalonate pathway generate geranylgeranyl di-
phosphate. Additional isopentenyl diphosphates are added by de-
caprenyl diphosphate synthase, which, in humans is a heterote-
tramer composed of two prenyl diphosphate synthase subunit 1
and two prenyl diphosphate synthase subunit 2 molecules. PHB is
derived from the amino acids tyrosine or phenylalanine. After PHB
and decaprenyl diphosphate are produced, at least seven enzymes
catalyze condensation, methylation, decarboxylation, and hydrox-
ylation reactions to synthesize CoQ10.
1,2
tical blindness. Brain magnetic resonance imaging (MRI)
showed bilateral symmetric areas of increased T2- and de-
creased T1-signal intensity in the basal ganglia, consistent
with Leigh syndrome (ﬁg. 2B). Urinary excretion of amino
acids and the acylcarnitine proﬁle in bloodwere at normal
levels.
Modiﬁed Gomori trichrome and cytochrome c oxidase
(COX) stains ofmuscle revealed increased proportions (4%–
7%) of ﬁbers with excessive subsarcolemmal mitochon-
drial aggregates (ﬁg. 2D), but no COX-negative ﬁbers were
present. Measurement of respiratory-chain enzyme activ-
ities in muscle and cultured ﬁbroblasts showed decreased
complex IIIII activities (muscle: 20 mU/U citrate syn-
thase, control range 37–285; ﬁbroblasts: 84 mU/U COX,
control range 160–440). Complex I activity was mildly
reduced in ﬁbroblasts (88 mU/U COX, normal range 110–
260) but normal inmuscle. Isolated activities of complexes
II, III, and IV were normal. After addition of decylubi-
quinone to the reaction mixtures, activity of complex II
III increased 8.9-fold in the patient’s muscle and 2.2-fold
in control muscle. Similarly, decylubiquinone addition
increased complex IIIII activity 4.7-fold in the patient’s
ﬁbroblasts and 3.6-fold in control ﬁbroblasts.
CoQ10 in muscle was extracted, mixing 50 ml of mus-
cle homogenate and 950 ml of 1-propanol, and CoQ10 in
ﬁbroblasts was extracted in hexane and was measured by
high-performance liquid chromatography with electro-
chemical detection (HPLC-EQ) by use of a reverse-phase
column and isocratic mobile phase.16 The results showed
that CoQ10 concentration was severely reduced in muscle
(4.6 mg/g tissue; mean  SD in 185 controls 32.1  6.8)
and ﬁbroblasts (patient 6.7  2.6 ng/mg protein; mean
in 10 controls 52.2  9.1). By use of the Stanbio choles-
terol Liquicor assay kit (Stanbio Laboratory), levels of cho-
lesterol were similar in ﬁbroblasts from the patient and
from controls (patient 5.6 mg/mg protein; mean of three
controls 6.7 2.1), thus excluding a defect in shared bio-
synthetic pathway of cholesterol and CoQ10.
Daily oral therapy with 500 mg L-carnitine, 5 mg biotin,
20 mg riboﬂavin, 50 mg thiamine, and, beginning at age
3 mo, 50 mg CoQ10 did not lead to clinical improvement.
The child died at age 8 mo because of severe refractory fo-
cal status epilepticus. The lack of clinical improvement
may have been due to poor CNS penetration of CoQ10,
the severity of brain damage prior to oral supplementa-
tion, or both.
We sequenced 11 known human genes (PDSS1 [MIM
#607429], PDSS2, COQ2, COQ3 [MIM *605196], COQ4,
COQ5, COQ6, COQ7 [MIM #601683], CABC1 [MIM
#606980], COQ9, and ADCK2) encoding COQ10 biosyn-
thetic proteins.2 We also sequencedCOQ10A andCOQ10B,
which encode proteins required for CoQ10 function in the
respiratory chain.17 Primer sequences and PCR conditions
for ampliﬁcation of candidate genes are listed in table 1.
We found two nonsynonymous nucleotide changes in
PDSS2, which encodes decaprenyl diphosphate synthase
subunit 218,19: a heterozygous CrT transition at nucleotide
964, changing amino acid 322 from glutamine to a stop
codon and a heterozygous CrT transition at nucleotide
1145, changing amino acid 382 from serine to leucine in
the seventh conserved domain in trans-prenyl diphosphate
synthase.19 The ﬁrst mutation was present in the father
and sister but not in the mother. The second transition
was present in the mother but not in the father and sister.
Both transitions were absent in DNA from 210 chromo-
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Table 1. Primers Used for PCR Ampliﬁcation and
Sequencing of CoQ10 Biosynthetic Genes
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2. A, At age 5 mo, the child was severely hypotonic. B, T2-weighted MR image of the brain at age 3 mo, showing bilateral
increased signal intensities at the putamen and globus pallidus, as well as increased white matter signal in the parieto-occipital regions
and atrophy in the occipital lobe and peri-insular region. C, EEG during right-sided focal status epilepticus, showing continuous high-
voltage 2-hz sharp waves over the entire right hemisphere. D, Gomori trichrome stain, demonstrating several muscle ﬁbers with abnormal
subsarcolemmal mitochondrial aggregates (500#). E, COX stain, showing a similar pattern of increased subsarcolemmal stain (400#).
somes tested by RFLP with use of Hpy188III and Hpy188I
restriction endonucleases (80% power to exclude 0.01
polymorphism frequency at ).20 No mutationsap 0.05
were found in the other CoQ10 biosynthetic genes.
To conﬁrm that the patients had a defect of CoQ10
biosynthesis, we measured the incorporation of two ra-
diolabeled substrates, 14C-PHB (50 Ci/mol) and 3H-deca-
prenyl-PP (20 Ci/mmol) in cultured ﬁbroblasts, as re-
ported.12 In the ﬁrst assay, cells were incubated with only
14C-PHB substrate, whereas, in the second assay, ﬁbroblasts
were incubated with two substrates (PHB and 3H-deca-
prenyl-PP). In both assays, radiolabeled CoQ10 was isolated
by HPLC with a C18 reversed-phase column and was col-
lected and quantiﬁed in a scintillation counter.12 In the
ﬁrst assay, the patient’s ﬁbroblasts incubatedwith 14C-PHB
showed decreased CoQ10 synthesis (patient, 402 83 de-
cays per min/mg protein/d; control mean 3,324  526
decays per min/mg protein/d, ) (table 2). However,np 5
in the second assay, the patient’s ﬁbroblasts incubated
with PHB and 3H-decaprenyl-PP synthesizedCoQ10 at rates
similar to control ﬁbroblasts (patientp 11.5 0.5 pmol/
mg protein/h; control meanp 14.29 2.3, ) (tablenp 5
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Table 2. Biochemical Assays for COQ10 Biosynthesis
Fibroblasts CoQ10 Biosynthesisa
% of
Control Mean
Assay 1b:
Control 3,324  526 DPM/mg protein/d 100
Patient 402  83 DPM/mg protein/d 12
Assay 2c:
Control 14.29  2.3 pmol/mg protein/h 100
Patient 11.5  0.5 pmol/mg protein/h 81
a In the three assays, radiolabeled COQ10 was isolated by HPLC and
was quantitated in a scintillation counter. Controls are measured as
means  SDs ( ). Patient measurements were realized per dupli-np 5
cated and the results are shown as means  SDs. DPM p decays per
minute.
b Cultured cells were incubated for 48 h with 0.1 mCi 14C-PHB (50 Ci/
mol speciﬁc activity).
c Fibroblast homogenates were incubated with 3H-decaprenyl-PP and
PHB for 1 h.
2), indicating that the CoQ10 biosynthetic pathway after
decaprenyl diphosphosphate synthase is intact (ﬁg. 1).
This result, combined with the defect of CoQ10 biosyn-
thesis detected with 14C-PHB, indicates that endogenous
levels of decaprenyl diphosphate are reduced in the pa-
tient’s ﬁbroblasts and support the pathogenicity of the
nucleotide changes in PDSS2.
PDSS2 encodes the second subunit of decaprenyl di-
phosphate synthase,18,19 which is considered one of the
rate-limiting enzymes in CoQ10 biosynthesis.
2,18,19 Saiki et
al.19 demonstrated that, in Schizosaccharomyces pombe,mice,
and humans, decaprenyl diphosphate synthases are het-
erotetrameric enzymes, formed by two protein subunits
encoded by PDSS1 (previously designated as “TPRT”) and
two protein subunits encoded by PDSS2. In the absence
of PDSS1 or PDSS2 (originally reported as “DPS1” and
“DLP1”),18,19 the enzyme is not functional and does not
produce CoQ10. Moreover, in mice and humans, two dif-
ferent PDSS2 transcripts have been identiﬁed: one en-
coded by eight exons and the other by four exons.19 Both
transcripts share the ﬁrst three exons. Saiki et al. demon-
strated that the ﬁrst transcript—but not the second—en-
codes a functional subunit of decaprenyl diphosphate syn-
thase.19 Consistent with the notion that the long tran-
script of PDSS2 is functionally important, both mutations
in our patient are localized in exon 6 and exon 8, which
are present only in the ﬁrst transcript.
In summary, this study reports the ﬁrst pathogenic mu-
tations in PDSS2 causing primary CoQ10 deﬁciency in an
infant with fatal Leigh syndrome and nephrotic syndrome.
Pathogenicity of these mutations is supported by (1) the
substitution of a stop codon for a glutamine and a hy-
drophobic leucine for a polar uncharged serine in two
conserved domains of decaprenyl diphosphate synthases;
(2) the absence of these mutations in 210 control chro-
mosomes; (3) the defect of CoQ10 synthesis in the patient’s
ﬁbroblasts when incubated with PHB contrasting with
normal synthesis in ﬁbroblasts incubated with PHB and
decaprenyl-PP. These assays conﬁrm that the biosynthetic
defect is impaired formation of decaprenyl diphosphate,
catalyzed by decaprenyl diphosphate synthase. Farnesyl
diphosphate and geranyl diphosphate are essential sub-
strates for decaprenyl diphosphate synthase and are gen-
erated by farnesyl diphosphate synthase and geranyl di-
phosphate synthase (ﬁg. 1). However, farnesyl diphosphate
and geranyl diphosphate are also necessary substrates for
cholesterol and dolichol synthesis.2 Since the cholesterol
level was normal in our patient’s ﬁbroblasts, defects in
farnesyl diphosphate synthase and geranyl diphosphate
synthase are unlikely.
Although 130 patients have been described with CoQ10
deﬁciency, the molecular defects have been identiﬁed in
only two other families. In the ﬁrst family, three sib-
lings and a cousin with cerebellar ataxia and CoQ10 deﬁ-
ciency had a mutation in the aprataxin gene, APTX (MIM
#606350), which is known to cause ataxia and oculomotor
apraxia 1 (AOA1 [MIM #208920]).21 In the second family,
the proband with infantile encephalomyopathy and ne-
phrotic syndrome and his younger sibling with nephrotic
syndrome had a homozygous missense mutation in COQ2,
which encodes PHB-polyprenyl transferase.11,12 Whereas
there is no obvious link between aprataxin and CoQ10 me-
tabolism, PHB-polyprenyl transferase catalyzes the second
step in CoQ10 biosynthesis, indicating that CoQ10 deﬁ-
ciency can be primary or secondary.
Mutations in PDSS2 should be considered as potential
causes of CoQ10 deﬁciency in other patients with similar
phenotypes, including two sisters with Leigh syndromeand
CoQ10 deﬁciency
13 and two siblings with severe encephalo-
myopathy, renal failure, and CoQ10 deﬁciency in whom
biochemical assays showed a defect in decaprenyl diphos-
phate synthase but no pathogenic mutation in PDSS1.9
Further studies of our patients and others with pri-
mary CoQ10 deﬁciencies should provide insights into
pathogenic mechanisms and genotype–phenotype rela-
tionships. Moreover, the availability of genetic testingwill
allow early deﬁnitive diagnosis and intervention for one
of the few treatable forms of mitochondrial encephalo-
myopathies. On the basis of the phenotypes of our pa-
tients with COQ2 and PDSS2 mutations, children with in-
fantile-onset encephalopathies with nephrotic syndrome
should be screened for primary CoQ10 deﬁciencies.
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